AbbVie
ABBV
$115.28
Share price
-1.38%
Change (1 day)
11.94%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Market capitalization of AbbVie (ABBV)
Market cap: $203.80 Billion
As of November 2021 AbbVie has a market cap of $203.80 Billion. This makes AbbVie the world's 57th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure how much a company is worth.
Market cap history of AbbVie from 2012 to 2021
| Year | Market cap | Change |
|---|---|---|
| 2021 | $205.97 B | 8.88% |
| 2020 | $189.17 B | 44.47% |
| 2019 | $130.94 B | -3.95% |
| 2018 | $136.33 B | -11.7% |
| 2017 | $154.39 B | 51.71% |
| 2016 | $101.76 B | 6.7% |
| 2015 | $95.37 B | -8.42% |
| 2014 | $104.14 B | 24.23% |
| 2013 | $83.82 B | 55.32% |
| 2012 | $53.97 B |
End of Day market cap according to different sources
On Nov 29th, 2021 the market cap of AbbVie was reported to be:
$206.64 Billion
$206.64 Billion
$205.97 Billion
$206.64 Billion
$206.56 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap difference | Country |
|---|---|---|---|
 Pfizer PFE | $301.57 B | 47.98% | 🇺🇸 USA |
 Eli Lilly LLY | $237.27 B | 16.42% | 🇺🇸 USA |
 Amgen AMGN | $112.02 B | -45.03% | 🇺🇸 USA |
 Biogen BIIB | $34.62 B | -83.01% | 🇺🇸 USA |
 Gilead Sciences GILD | $86.46 B | -57.57% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $119.03 B | -41.59% | 🇺🇸 USA |
 Astrazeneca AZN | $170.72 B | -16.23% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $103.45 B | -49.24% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $7.89 B | -96.12% | 🇺🇸 USA |